Repatha vs Lisinopril: What to Do When One Fails

Why These Two Drugs Are Not Interchangeable

Repatha and lisinopril work on completely separate physiological targets. Repatha (evolocumab 140 mg subcutaneous every two weeks, or 420 mg monthly) blocks PCSK9, a protein that degrades LDL receptors on hepatocytes, thereby driving LDL-C down by 55-60% on top of statin therapy [1]. Lisinopril (typical range 5-40 mg oral daily) inhibits angiotensin-converting enzyme, reducing angiotensin II, lowering systemic vascular resistance, and dropping blood pressure by roughly 8-10 mmHg systolic in clinical practice [2].

A patient whose LDL-C remains at 110 mg/dL despite high-intensity statin therapy has no reason to take lisinopril instead of Repatha. A patient with stage 2 hypertension and normal LDL-C has no reason to take Repatha instead of lisinopril. The two drugs are occasionally prescribed together in patients who carry both burdens, but they are not competing choices in a single drug slot.

When Cardiologists Prescribe Both Together

Atherosclerotic cardiovascular disease (ASCVD) is a multi-factorial condition. Patients with established coronary artery disease frequently have both elevated LDL-C and inadequately controlled blood pressure, which makes concurrent use of a PCSK9 inhibitor and an ACE inhibitor standard of care in many cardiology practices [3]. The ACC/AHA 2019 Guideline on the Primary Prevention of Cardiovascular Disease explicitly supports combining lipid-lowering and antihypertensive agents when individual risk factor targets are not met by a single agent [3].

The Shared Outcome Both Drugs Pursue

Both drugs reduce major adverse cardiovascular events (MACE), just through different mechanisms. In FOURIER (N=27,564), evolocumab added to statin therapy reduced the composite of CV death, MI, stroke, hospitalization for unstable angina, or coronary revascularization by 15% (HR 0.85, 95% CI 0.79-0.92, P<0.001) over a median 2.2 years [1]. In ALLHAT (N=33,357), lisinopril produced equivalent rates of fatal coronary heart disease or non-fatal MI compared with chlorthalidone, though it showed modestly higher rates of stroke (RR 1.15) and combined cardiovascular disease (RR 1.10) in that specific comparison [2].

Both results matter. They do not, however, make the drugs interchangeable.

What Does "Repatha Has Failed" Actually Mean?

Before switching anything, the prescribing clinician needs to define failure clearly. The word covers at least four distinct clinical situations, each requiring a different response.

Inadequate LDL-C Response

The most common form of Repatha failure is insufficient LDL reduction. ACC/AHA guidelines define an inadequate response as LDL-C remaining above 70 mg/dL in very-high-risk ASCVD patients after at least 4 weeks on a maximally tolerated statin plus evolocumab [3]. Possible causes include poor injection technique, missed doses (evolocumab's half-life is approximately 11-17 days, so a late injection still matters), or, rarely, homozygous familial hypercholesterolemia where PCSK9 inhibition is insufficient because the patient has almost no functional LDL receptors [4].

In this situation, the next step is not lisinopril. Lisinopril has no meaningful effect on LDL-C. Instead, the clinician should consider adding inclisiran (a small interfering RNA agent dosed twice yearly), ezetimibe if not already on board, or referring to a lipidologist for LDL apheresis evaluation in true homozygous FH [4].

Injection-Site Reactions or Injection Fatigue

Evolocumab is delivered subcutaneously. About 2.4% of patients in FOURIER reported injection-site reactions versus 1.5% on placebo [1]. Patients with needle phobia or occupational barriers to self-injection may also struggle with adherence. The practical response here is to switch to inclisiran (twice-yearly subcutaneous dosing administered in a clinic setting, removing the home-injection burden) or to alirocumab (Praluent), the other approved PCSK9 inhibitor, which some patients tolerate differently despite the same delivery route.

Again, lisinopril does not enter this decision tree.

Cost or Insurance Denial

Repatha listed at approximately $5,800 per year before manufacturer discounts. After prior authorization denials, many patients receive the drug at $0 through the Amgen patient assistance program, but the prior authorization process can delay therapy by weeks to months. A clinician who cannot get Repatha approved might consider alirocumab (same class, sometimes different formulary tier), bempedoic acid (oral, non-statin LDL-lowering), or ezetimibe as a bridge [4].

Lisinopril is generic and costs under $10 per month. It addresses a different problem entirely and would not be a cost-motivated substitute.

True Drug Intolerance

Myalgia from statins is common; evolocumab itself has a favorable tolerability profile with no significant increase in muscle-related adverse events over placebo in FOURIER [1]. Rare reports of neurocognitive effects (0.9% evolocumab vs. 0.8% placebo in FOURIER) have not been confirmed as causally drug-related by subsequent meta-analysis [1]. If a patient genuinely cannot tolerate evolocumab for a documented reason, the class-switch to inclisiran is the most logical move, not a shift to an antihypertensive.

What Does "Lisinopril Has Failed" Actually Mean?

Lisinopril failure is actually more clinically heterogeneous than evolocumab failure, because the drug carries several common side effects that force discontinuation.

The ACE Inhibitor Cough

Cough occurs in roughly 10-15% of patients on ACE inhibitors overall, and in up to 30-40% of patients of East Asian descent due to genetic variation in the bradykinin pathway [5]. This is the single most common reason lisinopril is stopped. When a patient develops a persistent dry cough attributable to ACE inhibitor therapy, the first-line switch is to an angiotensin receptor blocker (ARB) such as losartan, valsartan, or olmesartan. ARBs block the same renin-angiotensin-aldosterone system downstream of ACE without increasing bradykinin, so they do not cause cough [5].

Evolocumab has no antihypertensive effect. It would not be a substitute for lisinopril in this scenario.

Hyperkalemia

Lisinopril reduces aldosterone secretion, which promotes potassium retention. Patients with CKD stage 3b or higher (eGFR <45 mL/min/1.73 m²) or those concurrently using potassium-sparing diuretics are at particular risk [6]. Serum potassium above 5.5 mEq/L typically prompts dose reduction or discontinuation. The therapeutic replacement is usually an ARB at a lower-risk dose, or a switch to a calcium channel blocker (e.g., amlodipine) or thiazide diuretic for blood pressure control. Potassium binders such as patiromer can sometimes allow continuation of RAAS therapy in CKD patients at high ASCVD risk [6].

Angioedema

Angioedema occurs in 0.1-0.7% of ACE inhibitor users and is life-threatening in severe cases [7]. ACE inhibitor-induced angioedema is an absolute contraindication to re-challenge with any ACE inhibitor, and many guidelines also recommend against ARBs in patients with a history of ACE inhibitor angioedema due to residual risk, though ARBs carry a substantially lower risk [7]. Sacubitril/valsartan (Entresto) is contraindicated in patients with a history of ACE inhibitor-induced angioedema. In this patient, antihypertensive therapy pivots to calcium channel blockers, thiazides, or direct renin inhibitors depending on comorbidities.

Refractory Hypertension Despite Lisinopril

If blood pressure remains above 130/80 mmHg on maximum-dose lisinopril (40 mg/day), the standard next step is combination therapy. The ACC/AHA 2017 Hypertension Guideline recommends adding a calcium channel blocker or thiazide-type diuretic as a second agent, since two-drug regimens are approximately twice as effective as dose-doubling of a single agent [8]. Refractory hypertension (blood pressure uncontrolled on three agents including a diuretic) warrants investigation for secondary causes including primary aldosteronism, renal artery stenosis, or obstructive sleep apnea [8].

When a Patient Has Both Elevated LDL and Elevated Blood Pressure

This is the scenario where Repatha and lisinopril most frequently appear in the same chart. A 62-year-old male with established ASCVD, LDL-C 85 mg/dL on rosuvastatin 40 mg, and blood pressure 148/92 mmHg on no antihypertensive is a straightforward candidate for both drugs concurrently. There is no pharmacokinetic interaction between evolocumab and lisinopril. Neither drug meaningfully affects the other's mechanism.

A Practical Decision Framework for Dual-Risk Patients

The following logic applies when a patient has both conditions and one drug is not working:

1. Confirm which problem is uncontrolled (LDL, BP, or both) with objective numbers before any medication change.
2. If LDL-C remains above target on evolocumab, do not substitute lisinopril. Add ezetimibe, switch to inclisiran, or increase statin intensity.
3. If blood pressure remains above target on lisinopril, do not substitute Repatha. Add a calcium channel blocker, thiazide, or refer for resistant hypertension evaluation.
4. If a side effect forces discontinuation of one drug, switch within the same drug class before crossing drug classes.
5. Document the reason for the change specifically. "Failed therapy" is insufficient for insurance appeals; "LDL-C 92 mg/dL after 12 weeks on evolocumab 140 mg every two weeks plus rosuvastatin 40 mg" is sufficient.

Cardiometabolic Overlap: Where the Two Drugs Share a Patient Population

Patients with familial hypercholesterolemia (FH) have a roughly 35% prevalence of hypertension, according to registry data from the CASCADE FH Registry [9]. Patients with metabolic syndrome frequently carry both elevated LDL-C and hypertension. For these patients, the clinical question is not "Repatha or lisinopril" but "are both drugs at optimal dosing and are both risk factors at target?"

The 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies states: "For patients with very-high-risk ASCVD not at LDL-C goal despite maximally tolerated statin therapy, a nonstatin agent should be added without delay, independent of concurrent antihypertensive management" [10]. This explicitly decouples the two therapeutic decisions.

The American Heart Association's 2021 Guideline on the Evaluation and Management of Heart Failure likewise supports concurrent use of RAAS inhibition and lipid-lowering in patients with heart failure with reduced ejection fraction, a population that often requires both lisinopril (or its equivalent) and aggressive LDL management [11].

Blood Pressure and LDL Work Synergistically on Plaque

Mechanistic data from the FOURIER biomarker sub-study showed that patients with baseline high-sensitivity CRP above 2 mg/L had attenuated absolute benefit from evolocumab, suggesting that inflammatory burden modifies the LDL-lowering benefit [1]. Uncontrolled hypertension is itself a promoter of endothelial inflammation. A patient whose blood pressure remains 160/100 mmHg while on evolocumab is not extracting the full benefit of LDL reduction because the mechanical shear stress on coronary endothelium continues to drive plaque progression through a separate pathway [12].

This reinforces why both drugs, not one or the other, are needed in the highest-risk patients.

Side-Effect Profiles and What They Tell You About Class-Switching

Evolocumab Side Effects

In FOURIER, adverse event rates between evolocumab and placebo were notably similar across most categories [1]. Injection-site reactions: 2.4% vs. 1.5%. Neurocognitive events: 0.9% vs. 0.8% (P<0.001 was not reached, confirming no signal). Diabetes new-onset: no significant difference. The drug does not affect renal function, potassium, or blood pressure.

If a patient stops evolocumab due to a side effect, the class-switch to alirocumab or inclisiran is the appropriate path, not a pivot to a different drug class entirely.

Lisinopril Side Effects

The most common: dry cough (10-15%), dizziness on initiation (especially first-dose hypotension in volume-depleted patients), hyperkalemia (2-4% in CKD populations), and angioedema (0.1-0.7%) [7]. The most dangerous: angioedema, which requires immediate discontinuation and epinephrine if severe. Lisinopril is also absolutely contraindicated in pregnancy due to teratogenicity (Category D/X depending on trimester) [13].

Class-switching within antihypertensives (to an ARB, CCB, or diuretic) resolves most lisinopril failures without sacrificing blood pressure control.

Monitoring Protocols After a Medication Change

After Stopping or Switching Repatha

Check a fasting lipid panel 4-6 weeks after switching to a new LDL-lowering agent. LDL-C should fall within this timeframe if inclisiran or the new agent is effective. If switching to inclisiran, the initial dose is given, a second dose at 3 months, then every 6 months; the first LDL check should be at 3 months to confirm response [14].

After Stopping or Switching Lisinopril

Check blood pressure at 2-4 weeks after initiating the replacement antihypertensive. Check serum creatinine, BUN, and potassium at 1-2 weeks if the switch involves another RAAS agent (ARB), because acute kidney injury and hyperkalemia can still occur with ARBs in high-risk patients [6]. Target blood pressure per ACC/AHA 2017 is <130/80 mmHg in patients with ASCVD or diabetes [8].

Special Populations

Chronic Kidney Disease

Lisinopril carries additional benefit in CKD with proteinuria by reducing intraglomerular pressure. Evolocumab is renally safe and does not require dose adjustment in CKD. In a patient with CKD stage 3-4, elevated LDL, and hypertension with proteinuria, both drugs together with careful potassium monitoring represent best practice [6].

Heart Failure with Reduced Ejection Fraction (HFrEF)

Lisinopril (or enalapril) is a Class I recommendation in HFrEF with a survival benefit demonstrated in the SOLVD-Treatment trial (N=2,569), where enalapril reduced mortality by 16% (P<0.0036) over 41.4 months [15]. Evolocumab has not shown mortality benefit in HFrEF specifically, though LDL management is still recommended per ASCVD risk status. In this population, lisinopril failure is particularly high stakes and should be managed cautiously, ideally with cardiologist input.

Pregnancy

Lisinopril is contraindicated throughout pregnancy. Evolocumab's safety in pregnancy has not been established; available data are insufficient, and most clinicians stop PCSK9 inhibitors during pregnancy given the theoretical risk to fetal cholesterol synthesis [13]. Both drugs require a plan before conception in patients of childbearing potential.

Practical Summary for Clinicians

Neither drug replaces the other. Repatha failure triggers a move within lipid-lowering therapy. Lisinopril failure triggers a move within antihypertensive therapy. The two drugs occupy different lanes in cardiometabolic risk management and should be evaluated independently against their respective risk factor targets.

In patients who carry both elevated LDL-C and hypertension, the question is never "Repatha or lisinopril" but rather "are LDL-C and blood pressure both at goal, and if not, which drug regimen for each needs to change?"

Per the ACC/AHA 2019 Guideline on the Primary Prevention of CVD: "Combination pharmacological therapy targeting multiple risk factors simultaneously is appropriate when individual risk factor targets are not achieved with single-agent therapy" [3].

After any medication change in a high-risk ASCVD patient, obtain a fasting lipid panel at 4-6 weeks and a blood pressure check with metabolic panel at 2-4 weeks to confirm that both targets are moving in the right direction.